Keytruda/Inlyta Data Stoke Competition In Kidney Cancer
Competing combination therapies may soon be battling for attention as first-line therapies for advanced or metastatic renal cell carcinoma, with Merck & Co being the latest big pharma to release more data on the Keytruda/Inlyta combo in the setting.
You may also be interested in...
The German company is predicting sales in mid-triple-digits in 2019 for Mavenclad, its multiple sclerosis drug which has just been launched in the US, and has highlighted more promising MS data for its BTK inhibitor evobrutinib.
The latest drug development news and highlights from our US FDA Performance Tracker.
The changing competitive landscape in ovarian cancer, as well as disappointing earlier results in the condition, has led to the big pharma alliance ending the Phase III JAVELIN Ovarian PARP 100 study.